Eric A. Adams, MIBS
Chief Executive Officer & President
Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in
Bruce S. Colwill, CPA, CA
Chief Financial Officer
Mr. Colwill has more than 25 years of financial leadership experience in both public and private companies. Prior to InMed, Mr. Colwill served as Chief Financial Officer of General Fusion Inc., a private clean energy company. Mr. Colwill was also Learn More
Alexandra D.J. Mancini, MSc
Senior Vice President, Clinical & Regulatory Affairs
Ms. Mancini has more than 30 years of global biopharmaceutical R&D experience, overseeing a wide range of drug development activities, with a particular emphasis on clinical development and regulatory affairs. She has been an executive with numerous biotech
Eric C. Hsu, PhD
Senior Vice President, Pre-Clinical Research & Development
Dr. Hsu joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations.
Michael Woudenberg, P.Eng.
Vice President, Chemistry, Manufacturing & Controls
Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of
Shane Johnson, MD
SVP, General Manager of BayMedica
Dr. Shane Johnson’s career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.
Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane’s work has been focused on the cannabis and cannabinoid science space,
Philip Barr, PhD
VP, Discovery Research
As a graduate student, Dr. Phil Barr invented the antiviral compound Brivudine, which was approved for use in Europe. While Director of Molecular Biology at Chiron (now Novartis) and Adjunct Professor of Pharmaceutical Chemistry at UC San Francisco, Phil headed or worked with teams that used engineered yeast to successfully manufacture yeast-derived recombinant human insulin
Charles Marlowe, PhD
While at COR Therapeutics, Millennium Pharmaceuticals, Takeda and Exelixis Inc., Dr. Chuck Marlowe was instrumental in helping drive a number of small molecule therapeutics to entry into later-stage clinical trials and FDA approval. These products include Integrilin and Betrixaban (FDA-approved) , Cromafiban, XL147 and XL765 (Phase II, with Sanofi) and Elinogrel Phase III, with Novartis.
Jim Kealey, PhD
VP, Synthetic Biology
Dr. Jim Kealey has an extensive background in biochemistry, molecular biology, enzymology and synthetic biology. He has focused his research efforts using these skills to engineer organisms, including yeast, to produce small molecules, pharmaceuticals, and biofuels. At Intrexon, Jim built and managed a large research team that developed pioneering methods and platforms to convert inexpensive methane into higher value
Chris Meiering, PhD
VP, Commercial Operations
With a career spanning the scientific and consumer packaged goods industries, including over 20 years of leadership at Zuke's Performance Pet Nutrition (up through their acquisition by Purina), Dr. Chris Meiering brings a unique skill set to BayMedica. He is a scientist and self-directed business strategist with a history of innovation from concept to shelf and a proven track record bringing products to market.